Summary of findings table ‐ Methylprednisolone vs placebo: Number of participants with pain after 4 weeks
Methylprednisolone showed no clear difference in number of participants with pain after 4 weeks compared with placebo (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Methylprednisolone vs placebo Number of participants with pain after 4 weeks · patients with Guillain‐Barré syndrome, with varying severities of pain Methylprednisolone showed no clear difference in number of participants with pain after 4 weeks compared with placebo (low certainty). Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane Headline outcomes only | RR 0.89 [0.68, 1.16] | 1 study · 223 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Pharmacological treatment for pain in Guillain‐Barré syndrome 2015 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.